Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015

Eli Lilly and Company will present early-stage data from several targeted cancer therapies, reflecting Lilly's diverse oncology pipeline, during the American Association for Cancer Research (AACR) Annual Meeting 2015, held April 1822 April in Philadelphia, PA.

"Bringing Cancer Discoveries to Patients" is the theme of this year's AACR meeting and one that is mirrored through Lilly's commitment to broadening its portfolio of therapies that accelerate the pace and progress of cancer care. Lilly research to be presented at AACR represents findings from several of its oncology pipeline compounds in various stages of development.

"The research we present at AACR will set the stage for the next generation of therapies from Lilly," said Richard Gaynor, senior vice president of product development and medical affairs for Lilly Oncology. "Each step we take in the course of our research — both in the lab and in clinical trials — leads us toward the same overall goal: to increase the number of life-changing medicines and innovative solutions available to patients."

Titles of the presented abstracts are as follows:

• Abstract #3101: In-vitro characterization of abemaciclib pharmacology in ER+ breast cancer cell lines

• Abstract #CT240: Checkpoint Kinase (CHK) 1/2 Inhibitor LY2606368 in a Phase I Dose-Expansion Study in Patients with Squamous Cell Carcinoma of the Head and Neck

• Abstract #2142: Novel Oncogenic BRaf Deletions Functioning as BRaf Homodimer and Sensitive to Inhibition by LY3009120, a Pan Raf and Raf Dimer Inhibitor